Study of Eribulin in Children With Cancer to Determine Safety

• Status: Terminated
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigators will be monitoring the children on this study for the safety of the treatment and levels of eribulin in the blood after treatment. The investigators will also study the effect of the agent on the cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma

Criteria

Inclusion Criteria:

• Age: ≤ 21 years of age at the time of study enrollment

• Diagnosis: refractory or recurrent solid tumors, including lymphomas, except those with CNS tumors or known CNS metastases

• Disease Status: measurable or evaluable disease

• Adequate organ function as defined in protocol

Exclusion Criteria:

• Pregnant or breastfeeding